Kwality Pharmaceuticals Limited (BOM:539997)
| Market Cap | 35.74B +219.4% |
| Revenue (ttm) | 5.54B +37.9% |
| Net Income | 810.45M +86.7% |
| EPS | 78.10 +86.8% |
| Shares Out | 10.38M |
| PE Ratio | 44.10 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,670 |
| Open | 3,502.00 |
| Previous Close | 3,444.75 |
| Day's Range | 3,501.95 - 3,725.45 |
| 52-Week Range | 828.80 - 3,725.45 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 10, 2026 |
About Kwality Pharmaceuticals
Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including capsules, eye and ear drops, ointments and creams, pouches and sachets, sanitizers, tablets, suppositories, injectable vials and ampoules, liquid orals, lyophilized products, syrups, and various other categories, such as general, beta-lactam, cephalosporins, oncology, biologics, and hormones and specialty injectables. It also provides int... [Read more]
Financial Performance
In fiscal year 2026, Kwality Pharmaceuticals's revenue was 5.03 billion, an increase of 35.90% compared to the previous year's 3.70 billion. Earnings were 673.46 million, an increase of 69.02%.
Financial StatementsNews
Kwality Pharmaceuticals Transcript: Q1 26/27
Revenue guidance for FY 2027 is raised to over INR 700 crore with EBITDA margins of 26%-27%, driven by new product registrations and expansion in LATAM and MENA regions. Major CapEx is planned for hormone, oncology, and biosimilar programs, with strong growth expected through FY 2030.
Kwality Pharmaceuticals Quarterly report: Q1 2027
Kwality Pharmaceuticals has published its Q1 2027 quarterly earnings report on August 10, 2026.
Kwality Pharmaceuticals Slides: Q1 2027
Kwality Pharmaceuticals has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 10, 2026.
Kwality Pharmaceuticals Quarterly report: Q4 2026
Kwality Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 19, 2026.
Kwality Pharmaceuticals Annual report: Q4 2026
Kwality Pharmaceuticals has published its Q4 2026 annual report on May 19, 2026.
Kwality Pharmaceuticals Quarterly report: Q3 2026
Kwality Pharmaceuticals has published its Q3 2026 quarterly earnings report on February 11, 2026.
Kwality Pharmaceuticals Slides: Q3 2026
Kwality Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 11, 2026.
Kwality Pharmaceuticals Quarterly report: Q2 2026
Kwality Pharmaceuticals has published its Q2 2026 quarterly earnings report on November 12, 2025.
Kwality Pharma receives product registration for Bleomycin 15 IU per vial in Mexico
Kwality Pharmaceuticals Ltd has announced that it has received registration approval for Bleomycin 15 1U in Mexico, enabling the company to begin sales and distribution in the region. Bleomycin is a w...
Kwality Pharmaceuticals shares jump 17% after Q4 net profit surges 232% YoY
Shares of Kwality Pharmaceuticals surged 16.85% to ₹964.90 in early trade on Tuesday after the company posted a stellar set of numbers for the fourth quarter ended March 2025. The stock hit a high of ...
Kwality Pharmaceuticals receives GMP approval from SFDA for its two manufacturing units in Amritsar
Kwality Pharmaceuticals Limited has achieved a significant milestone by securing GMP (Good Manufacturing Practice) approval for its two audited manufacturing units in Amritsar. This prestigious certif...
Kwality Pharmaceuticals receives RCGM approval for pre-clinical studies of recombinant Erythropoietin
Kwality Pharmaceuticals Limited (KPL) announced a major milestone, securing approval from the Review Committee on Genetic Manipulation (RCGM) to advance pre-clinical toxicity studies for its recombina...
Kwality Pharmaceuticals gets SAHPRA approval in South Africa for Tamoxifen 20mg tablet
Kwality Pharmaceuticals Ltd. (KPL) proudly announces the approval of its oncology oral solid dosage (OSD) product, Tamoxifen 20mg Tablet, by the South African Health Products Regulatory Authority (SAH...